ZYUS Life Sciences Balance Sheet Health
Financial Health criteria checks 3/6
ZYUS Life Sciences has a total shareholder equity of CA$23.1M and total debt of CA$6.8M, which brings its debt-to-equity ratio to 29.4%. Its total assets and total liabilities are CA$41.6M and CA$18.5M respectively.
Key information
29.4%
Debt to equity ratio
CA$6.79m
Debt
Interest coverage ratio | n/a |
Cash | CA$5.85m |
Equity | CA$23.11m |
Total liabilities | CA$18.51m |
Total assets | CA$41.63m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: ZYUS's short term assets (CA$9.4M) do not cover its short term liabilities (CA$13.2M).
Long Term Liabilities: ZYUS's short term assets (CA$9.4M) exceed its long term liabilities (CA$5.3M).
Debt to Equity History and Analysis
Debt Level: ZYUS's net debt to equity ratio (4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ZYUS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZYUS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ZYUS has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 30.2% each year.